Hemodynamic Effects of Methylene Blue vs Hydroxocobalamin in Patients at Risk of Vasoplegia During Cardiac Surgery

Withdrawn before enrolling · Phase 2

Conditions studied: Vasoplegia, Hypotension, Coronary Artery Disease, Cardiac Valve Disease

In brief

This is a pilot study to determine the hemodynamic effects when hydroxocobalamin vs methylene blue is administered during cardiopulmonary bypass in patients at risk of vasoplegia by measuring mean arterial pressure (MAP), systemic vascular resistance (SVR) and vasopressor requirement.

Key facts

Study ID
NCT03446599
Run by
Dartmouth-Hitchcock Medical Center
People needed
0
Starts
2019-11-01
Expected to finish
2020-06-30
Last updated by the study team
2020-03-02

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.